Blonanserin

Blonanserin is an atypical antipsychotic agent, developed by Dainippon Sumitomo Pharma. It was first introduced in Japan in 2008 for the treatment of schizophrenia. The drug is also available in South Korea and China. Blonanserin has a high affinity for dopamine D2 receptors and serotonin 5-HT2A receptors, which is believed to contribute to its antipsychotic activity.

Etymology

The name "Blonanserin" is derived from the chemical structure of the compound, which contains a blon group (a type of chemical structure) and an anserin group (another type of chemical structure).

Pharmacology

Blonanserin acts as an antagonist at several neurotransmitter receptors. It has a high affinity for dopamine D2 and D3 receptors, and serotonin 5-HT2A and 5-HT2C receptors. It also has a moderate affinity for histamine H1 and alpha1-adrenergic receptors, and a low affinity for serotonin 5-HT1A receptors and alpha2-adrenergic receptors. The antagonism of D2 receptors is thought to be responsible for the antipsychotic effects of blonanserin.

Clinical Use

Blonanserin is used in the treatment of schizophrenia. It has been found to be effective in reducing both positive and negative symptoms of the disorder. Positive symptoms include hallucinations, delusions, and thought disorder, while negative symptoms include lack of motivation, reduced emotional expression, and social withdrawal.

Side Effects

Common side effects of blonanserin include somnolence, akathisia, and weight gain. Less common side effects include extrapyramidal symptoms, hyperprolactinemia, and orthostatic hypotension. Rare but serious side effects include neuroleptic malignant syndrome and tardive dyskinesia.

See Also

• Atypical antipsychotic
• Dopamine D2 receptor
• Serotonin 5-HT2A receptor
• Schizophrenia

Blonanserin

• 
  Blonanserin
• 
  Blonanserin crystal structure